COMMUNIQUÉS West-GlobeNewswire

Noom Unveils Two New Enterprise Products to Help Employers Offer, Manage, and Effectively Control GLP-1 Expenses

21/10/2024 - 14:02

Noom Med with Smart Rx , in partnership with Waltz Health, drives significant ROI for employers who wish to cover GLP-1s as a supplemental benefit such that the payer can choose the level of financial assistance they [...]

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

21/10/2024 - 14:01

Revenue increases 4% year over year while loss from operations decreases by 32% Pooled Results of ColoFuture and eAArly DETECT studies published at ASCO showing groundbreaking performance with sensitivity for CRC of 92 [...]

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

21/10/2024 - 14:00

Remain on track to initiate registrational THRIVE-3 trial in 1Q’ 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies [...]

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

21/10/2024 - 14:00

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related [...]

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

21/10/2024 - 14:00

Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience TAMPA, Fla., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the [...]

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

21/10/2024 - 14:00

FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial [...]

COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024

21/10/2024 - 14:00

Detailed safety and efficacy results to be presented Data show potential of CNP-104 to slow disease progression as demonstrated by statistically significant decrease in liver stiffness compared with placebo CHICAGO, Oct [...]

Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma

21/10/2024 - 14:00

FDA sets a PDUFA target action date of March 20, 2025 Resubmission is supported by the final survival analysis of CARES-310 study, presented at ASCO 2024 FORT LEE, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Elevar [...]

Windtree To Present at the ThinkEquity Conference on October 30th

21/10/2024 - 14:00

WARRINGTON, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for [...]

Life Biosciences Presents at AAO Highlighting Progress of Nonhuman Primate Studies Evaluating Partial Epigenetic Reprogramming to Restore Visual Function

21/10/2024 - 14:00

Data replicate and expand upon the potential of ER-100 to improve retinal ganglion cell function and restore visual function in a nonhuman primate model of nonarteritic anterior ischemic optic neuropathy (NAION) BOSTON [...]

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

21/10/2024 - 14:00

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

21/10/2024 - 14:00

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Aveanna to Participate Virtually at the Stephens Annual Investment Conference

21/10/2024 - 13:30

ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Stephens Annual Investment Conference. Management will host [...]

Finch Announces Delisting from Nasdaq and SEC Deregistration

21/10/2024 - 13:30

BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today [...]

KFSHRC Successfully Conducts Pharmacogenetic Analysis for Over 1,500 Patients

21/10/2024 - 13:14

RIYADH, Saudi Arabia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Since its launch in early September last year, King Faisal Specialist Hospital & Research Centre (KFSHRC) has successfully conducted pharmacogenetic analysis [...]

Kraig Biocraft Laboratories to Host Upcoming Investor Web Conference Highlighting Commercialization Progress of Spider Silk Technologies

21/10/2024 - 13:05

ANN ARBOR, Mich., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of spider silk-based fibers, today announced plans to host an [...]

Optimal Breathing is Excited to Launch the HSA/FSA Payment Option

21/10/2024 - 13:03

FORT MILL, S.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Optimal Breathing is proud to have launched the HSA/FSA payment option on October 18, 2024. You can now use your Health Savings Account (HSA) and Flexible Spending [...]

BioCryst to Report Third Quarter 2024 Financial Results on November 4

21/10/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on Monday, November 4, [...]

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

21/10/2024 - 13:00

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]